A Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Japanese and Caucasian Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Tibulizumab (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2018 Status changed from not yet recruiting to recruiting.
- 17 Nov 2018 New trial record